MEAN LOG IAA vs Time to DM from age Islet Ab first +

-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.00

5

10

15

log10 Mean Insulin Abs

Tim

e to

DM

fro

m a

ge 1

stA

b+R2=.37 P<.0001

Steck et al Diabetes Care 2011

GAD65 Levels with Years to Diabetes

-3.5 -3.0 -2.5 -2.0 -1.5 -1.0 -0.5 0.00.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

Mean GAD65 Levels (Log10)

ICA512 Levels with Years to Diabetes

-4 -3 -2 -1 00.0

2.5

5.0

7.5

10.0

12.5

15.0

17.5

Mean ICA512 Levels (Log10)

Steck et al Diabetes Care 2011

Age 1st Islet Ab+ vs Age DM Onset

0.0 2.5 5.0 7.5 10.0 12.50

5

10

15

AGE 1st Islet Autoantibody +

AG

E D

IAB

ET

ES

ON

SE

T

R2=.47 p<.0001

Steck et al Diabetes Care 2011

Progressive Loss C-peptide Post Diagnosis (SEARCH Diab Care 2009)

DCCT Fast>=.23ng/ml

ACCELERATED LOSS OF PEAK C-PEPTIDE AFTER DIAGNOSIS OF TYPE 1A DIABETES (“WAITING” FOR CONFIRMATORY ORAL GLUCOSE TOLERANCE TEST)

Sosenko et al, Diabetes Care August 2008

New Onset Type 1 DM: Loss of Insulin Secretion (ISR area(AUC)) related to early (peak<45 min) versus delayed secretion Mixed Meal Steele et al Diabetes 53:26, 2004

Type 1 diabetes risk stratification models based on islet autoantibody characteristics

Model 1 Model 2 Model 3 Model 4

Number ofislet autoantibodies(IAA, IA-2A, GADA)

High titre ofIAA (>3rd quart.)

and IA-2A (>1st quart.)

High risk characteristics:High titre IA-2A (>1st quart.)

and IgG2 or IgG4 IA-2Aand IgG2, IgG3 or IgG4 IAA

Status ofIA-2A and IA-2βA

Category 1One autoantibody

Category 2Any two

autoantibodies

Category 3All three

autoantibodies

Stratification based on

Category 1Neither IAA nor IA-2A

at high titre

Category 2One of IAA or IA-2A

at high titre

Category 3Both of IAA and IA-2A

at high titre

Category 1No high risk

characteristic

Category 2One high riskcharacteristic

Category 3Any two high risk

characteristics

Category 4All three high risk

characteristics

Category 1IA-2A negative

Category 2IA-2A positive andIA-2βA negative

Category 3IA-2AβA positive

Stratification based on Stratification based on Stratification based on

Shaded Categories: 10-year diabetes risk >50% (high-risk categories)Achenbach et al., Diabetologia (2006) 49:2969-2976

100

80

60

40

20

0

100

80

60

40

20

0

Dia

bete

s-fr

e e s

u rv i

v al (

%)

Model 1 Model 2 Model 3 Model 4

Follow up (years)

P = 0.02 P < 0.001 P < 0.001 P < 0.001

P = 0.02

2 4 6 8 100 12 2 4 6 8 100 12 2 4 6 8 100 12 2 4 6 8 100 12

Stable low-risk category

Changed from low-risk to high-risk categoryStable high-risk category

Changed from high-risk to low-risk category

Type 1 diabetes risk stratification considering changes in model risk category on follow-up

Achenbach et al., Diabetologia (2006) 49:2969-2976

Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect

evidence for islet regeneration?Meier et al, Diabetologia 2005

0

0.2

0.4

0.6

0.8

1

1.2

Diabetes Control

% Insulin/Pancreatic Area

Time Course of Beta Cell Loss

Linear, Chronic ModelEisenbarth (NEJM 1986, 314:1360)

Benign:Malignant ModelLafferty (J Aut 1997, 10:261)

Random Loss ModelPalmer (Diabetes 1999, 48:170)

Age

Age

BetaCell Mass

BetaCell Mass

Age

Benign Malignant

BetaCell Mass

Time Course Beta Cell Loss

Linear: Eisenbarth

NEJM 1986, 314:1360

Prodrome> Acute

Lafferty; J Aut 1997, 10:261

Random:Palmer

Diabetes 1999, 48:170

LOSS OF FIRST PHASE INSULIN RESPONSE

TIME

Stages in Development of Type 1 Diabetes B

ETA

CE

LL

MA

SS

DIABETES

“PRE”-DIABETES

GENETICPREDISPOSITION

INSULITISBETA CELL INJURY

NEWLY DIAGNOSED DIABETES

MULTIPLE ANTIBODY POSITIVE

GENETICALLY AT RISK

J. Skyler

T1DM- a slowly progressive T-cell mediated autoimmune illness

Geneticsusceptibility

IsletCellMass

100%

50%

0%

IncitingEvent(s)

“Brittle”Diabetes

III III

Time (years)

“Silent” Cell Loss

We cannot easily/accurately measure islet mass in vivo or ex vivoNo accepted norm for the islet number within a human pancreas

Strong association with MHC class II (DQ in particular)Other associations much weaker, population dependent- e.g. insulin VNTR, CD152, other

Infectious agent(s)?- Etiology if true?Environmental toxin(s)?Absence of childhood illness?Combination of factors?Age of exposure?

DiabetesOnset

b cellMass??

Is cell masscompletely lost?

Can cellregeneration occur?

Is cell lossexclusively

immune mediated?

What is the “slope” of the cell loss?Is recovery possible once process begins?What underlies the effect of age on slope of cell loss?Why does the cell destruction typically occur slowly (in contrast to graft rejection)?

David Harlan

Diagnosis of Diabetes ADANORMAL IMPAIRED DIABETES

HbA1c <6.4 5.7-6.4 >=6.5

FASTING < 100 mg%(5.6 mM)

100-125 >= 126 mg%(7 mM)

ORAL GTT <140 mg%(7.8 mM)

140-199 >=200 mg%(11.1 mM)

Gestational Diabetes (>=2 high)100-g or 75-g Glucose

mg/dl mmol/l100-g GlucoseFasting 95 5.31-h 180 102-h 155 8.63-h 140 7.875-g GlucoseFsting 95 5.31-h 180 102-h 155 8.6

“Stages” in Development of Type 1A Diabetes

Age (years)

Genetic Predisposition

Bet

a ce

ll m

ass

(?Precipitating Event)

Overtimmunologicabnormalities

Normal insulinrelease

Progressiveloss insulinrelease

Glucosenormal

Overtdiabetes

C-peptidepresent

NoC-peptide

Age

Intr

aven

ou

s G

luco

se T

ole

ran

ce T

est

(IV

GT

T)

1+3

min

ute

insu

lin

Srikanta S. et al, New Engl J Med 308:322-325, 1983

Antibody Positive Initial Test

Antibody Positive

Discordant Triplets at Risk for Diabetes

0

50

100

150

200

250

300

350

14 16 18 20 21 22 24 27 30 34 35 36 37 38 40 42 43 44 45 46 47 48 49 50 14 15 16 17 18 19 20 21 22 23

DM

“Biochemical” Autoantibody Assays

• Insulin

• Glutamic Acid Decarboxylase

• ICA512 (IA-2)

DPT-1 Ancillary Biochemical Ab

• Cytoplasmic ICA Positive (3.4%)1/2 Negative for GAD/ICA512/Insulin Ab0.9% = 1 Biochemical Ab1.1% >=2 Ab

• Cytoplasmic ICA Negative (96.6%)3.3% =1 “Biochemcial Ab 0.3% >=2 Ab

• Staging: Only 12% eligible ICA+/Bioch -• Future Trials Likely without ICA

0

20

40

60

80

100

0 2.5 5 7.5 10 12.5 15

3 Abs2 Abs1 Ab

Progression to Diabetes vs Number of Autoantibodies(GAD, ICA512, Insulin)

Percent not Diabetic

Years of Follow-up

3 Ab n = 41 17 8 1 2 Abs n = 44 27 15 4 2 11 Abs n = 93 23 14 10 6 4 Verge et al. Diabetes,

1996;45;926

Gestational Diabetes: Risk at 2 years Type 1 Diabetes by Autoantibodies

ICA, GAD65, ICA512(IA-2)

0

10

20

30

40

50

60

70

80

90

0 Ab >=1 Ab 1 Ab 2 Ab 3 Ab

Sensitivity GAD=63%; Sensitivity 3 Abs=82%

Ziegler et al. Diabetes 1997: 46:1459-67, N=437

LADA: Latent Autoimmune Diabetes Adults in UKPDS study

0

5

10

15

20

25

30

35

AGE

05

1015202530354045

% GAD + Insulin by 6 Years

Turner et al. Lancet 1997;350:1288-93

Caveats of IVGTT Testing

Caveat Suggestion"First" Test lack responseyoung children

Repeat Abnormal Tests

Lack Carbohydrate Dietary Preparation similarto OGTT

Type 1A and insulinresistance may coexist

Subtract 2X fasting insulin

Can be <1st Percentile inadults years prior to DM

Long-term follow up

Subset normals <1st % In absence Abs low risk

Variation e.g. puberty Repeat tests; caution ininterpreting changes

First-phase insulin release during the intravenous glucose tolerance test as a risk factor for type 1

diabetes (DPT)

Chase et al. J. Peds 138,244; 2,001

0

50

100

150

200

2501+

3 M

inut

e In

sulin

(uU

/ml)

ICA Negative

ICA Positive

<8 8-20 21-30 31-45AGE BDC

FPIR in pre-diabetic relatives with initial FPIR > 50mU/L

-8 -7 -6 -5 -4 -3 -2 -1 0

5

50

500

Years prior to diabetes

log

FP

IR (

1+

3' in

su

lin

)

Melbourne Pre-Diabetes Study (Colman PG & Harrison LC)

EARLY LOSS IVGTT ICA+ INFANTS: Individual insulin concentrations during IVGTTs

performed to A) ICA negative children 1–5 years of age, B) ICA positive children who had not progressed

to diabetes by May 2001, and C) ICA positive children who had developed clinical Type I diabetes by May

2001. (From: Keskinen P, Korhonen S, Kupila A, Veijola R, Erkkila S, Savolainen H, Arvilommi P, Simell T, Ilonen

J, Knip M, Simell O: First-phase insulin response in young healthy children at genetic and immunological risk for

Type I diabetes. Diabetologia 45:1639-48, 2002)

Insulin (

mU/l)

0 1 2 3 4 5 6 7 8 9 10 0 1 2 3 4 5 6 7 8 9 10

0

20

40

60

80

100

120

140

160

180

0 1 2 3 4 5 6 7 8 9 10

Insulin Secretion (IVGTT) in Obese Child (BMI 30 to 35) Progressing to Diabetes: Type

1 + Type 2 with Elevated Fasting Insulin

0

50

100

150

200

250

9 10 11 12 13 14 15

Age (years)

Insu

lin

(uU

/ml)

1+3 Insulin2X Fast

Lack of Progression to DM of ICA+ 0602+ Relatives

0

25

50

75

100

0 2 4 6 8 10 12

Years of Follow up

Per

cent

Not

Dia

beti

c

0602+ 0602-

Number Abs: IVGTT > or <1st%

0

20

40

60

80

100

0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0

Years of Followup

Per

cent

Not

Dia

beti

c

1Ab <1st 2Ab <1st 3Ab <1st 1Ab >1st 2Ab>1st 3Ab>1st

Melbourne Data: Dual Parameter PredictionTime to DM=-.12+1.35ln(IVGTT)-.59ln(IAA)

0

20

40

60

80

100

0 2 4 6 8

Years of Follow up

Per

cen

t N

ot

Dia

bet

ic

Predict<2.5

Predict>2.5

<2.5 N= 11 5 3 1 0

>2.5 N=70 53 42 32 24 13 6 Proc AAP:110:126-135

Normal but increasing hemoglobin A1c levels predict progression from islet autoimmunity to overt type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). Stene Pediatr Diabet 2005

DM

Blood glucose values inControl vs. Daisy children

DAISY Control-FH Control no FH0

200

400

600

800

1000

1200

1400

Blo

od

glu

cose

, m

d/d

L

Barker et al. DiabetesCare, 2004; 27:1399-1404.

Diabetes Autoimmunity Study in the Young

Sibling/offspring cohortGeneral population cohort

enrolled = 293 high risk 72

429 moderate risk 220

347 average - low risk 401

1,069 All 693

relatives 1,491 1,007

screened = 21,713

DAISY Interviews and ClinicalInterviews: diet

infectionsimmunizationsallergiesstress

B 3m 6m 9m 1y 15m 2y 3y

Clinical Visits: blood sample for GAA, IAA, ICA512, ICA DNA

throat and rectal swabs saliva sample

Visits

Prediction of Autoantibody Positivity and Progression to Type 1 Diabetes: DAISY study

Barker et al. J Clin Endocrinol Metab 89:3896, 2004

Of 1,972= 8.2%

1/3

1/3 1/3

1/3 of Multiple Time+ are Transient (22/(22+24+28)

2/3 High Risk Diabetes

DAISY AUTOANTIBODIES:Initial Test <Age 1

0 1 2 3 40

20

40

60

80

100

Percent with Persistent Autoantibodies (GAA/IAA/ICA512)

3/4SOC

3/4NEC

not 3/4SOC

not 3/4NEC

3/4 SOC: 15 9 5 43/4 NEC: 151 110 67 18-3/4 SOC: 69 56 39 16 3-3/4 NEC: 492 300 208 110

p<.0001

12/27/97

Relatives (SOC) vs. Population (NEC)Persistent vs. Transient AutoAb

0

5

10

15

20

25

30

35

Per

cent

PERSISTENT TRANSIENT

SOC 3/4SOC # 3/4NEC 3/4NEC #3/4

Yu et al. JCEM 85: 2421, 2000

0

10

20

30

40

50

60

70

80

90

100

Affin>10(9) Multipe Absf/u

Diabetes Proinsulin

High Risk "False Positive"

PERCENT

Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. Achenbach et al, J.Clin Invest 2004, 114:589

Candidate environmental causes of type 1 diabetes

• Definite (rare cases)– congenital rubella

• Putative– enteroviruses – rotaviruses– components of infant diet

• gluten• cow’s milk

Enteroviruses: Recent Studies

Study Autoimmunity Diabetes

Frisk 1992 CVB1-5 IgM

Dahlquist 1995 CVB2-4 IgM

Hyoty 1995 IgM,IgG CVB CVB IgM,IgG

Clements 1995 EV RNA

Graves(DAISY)1996,2000

No EV RNA(RNA 12%:18%)No EV IgM

No EV RNA

Hyoty (DIPP)2000 (<6mos.)

EV Ab:57%:31%EV RNA: 29% 6%

Autoantibody development and enteroviral RNA

in a HLA-DR3/4,DQB1*0302 sibling

0.1

1.0

10.0

100.0

1000.0

0.8 1.1 1.4 1.8 2.4 2.7 3.0 3.3 3.6 3.8 4.2 4.9 5.5

GAAIAA

ICA512TGIgA

SD score

Age [yrs]

EV- EV+ EV- EV+ EV+ EV- EV+ EV+ EV- EV- EV- DAISY ID 00060

ECHO 16

Beta-cell autoimmunity and presence of enteroviral RNA in serum, saliva and stool

Graves PM, DAISY, 1999

0%

10%

20%

30%

Relatives High risk childrenfrom the general

population

CasesControls

Prevalence of EV RNA

3/13 3/13 3/14 6/28

DIPP Protocol

Main Cohort (n=38,000)

• Newborns screened for genetic risk

• High risk babies followed serially for ICA (n=81)

• ICA-positive children randomized to nasal insulin or placebo

Trials to Prevent Type 1 Diabetes

• Trialnet/DPT-1

• ENDIT

• TRIGR

• DIPP

0 2 4 6 8Age (years)

0

5

10

15

20

Cum

ulat

ive

Ab

freq

uenc

y (%

)

DR3/4-DQ8

DR4/4-DQ8

Moderate DR4-DQ8

Moderate DR3Protective

Neutral

Development of islet autoantibodies in 1610 offspring of mothers or fathers with T1D

Walter et al, Diabetologia 2003 (updated 2004)

Age (years)

Cum

ulat

ive

Ab

freq

uenc

y (%

)

DR3/4-DQ8 or 4/4-DQ8+ INS VNTR I/I

Other

Development of islet Abs - HLA DR-DQ and INS VNTR genotypes

0 2 4 6 8

0

5

10

15

20

25

30

DR3/4-DQ8 or 4/4-DQ8+ INS VNTR I/III or III/III

Walter et al, Diabetologia 2003 (updated 2004)

P = 0.03

0 2 4 6 8

0

5

10

15

20

25

30

Mu

ltip

le a

uto

antib

od

ies

(%) both parents or

parent + sibling

mother only

father only

Age (years)

P = 0.05

Development of islet Abs - proband

P < 0.0001

A. Ziegler

0 2 4 6 8

Time from first autoantibody positive (years)

0

20

40

60

80

100

Both parents or Parent plus siblingMother onlyFather only

0 2 4 6 8

Type

1 d

iabe

tes

(%)

0

20

40

60

80

100

HighNeutral or ProtectiveModerate

HLA Proband

Progression from multiple islet Abs to diabetes - No effect of HLA DR-DQ or proband

A. Ziegler

0 2 4 6 8 100

2

4

6

8

10

Islet autoantibody appearance in BABYDIAB offspring

Age (years)

Any islet Abs (7.8%)

Multiple islet Abs (3.7%)

Single islet Abs

Hummel et al., Ann Intern Med, June 2004A. Ziegler

Time from first Ab (years)

Dia

bete

s (%

)

86420

100

80

60

40

20

086420

100

80

60

40

20

0

multiple antibodies

Single IAA

Hummel et al., Ann Intern Med, June 2004

Progression to multiple Abs is necessary for disease

A. Ziegler

Progression

Insulin

GAD

IA-2

A. Ziegler

First antibody is insulin/proinsulin

1086420

8

6

4

2

0

IAA

IA2A

GADA

1086420

8

6

4

2

0

Age (years)

Cu

mu

lativ

e fr

equ

ency

(%

)

A. Ziegler

104

105

106

107

108

1010

1011

IAA

Aff

init

y (L

/mo

l)109

1012

multipleAbs

IAAonly

IAA affinity is high in children who developmultiple islet Abs

P<0.0001

Achenbach, J Clin Invest, 2004 A. Ziegler

105

106

107

108

109

1010

1011

IAA

Affi

nity

(L/

mol

)

0 1 2 3 4 5 6 7 8 9 10

Age (years)

1211

1012

104

IAA affinity is relatively stable during follow-up

A. Ziegler

100

80

60

40

20

0

% w

ith m

ultip

le is

let a

bs

0 21 43

Progression to multiple islet autoantibodies in children is related to IAA affinity

IAA affinity high

IAA affinity low

P = 0.0004

IAA positive follow-up (years)A. Ziegler

Risk for developing islet Abs in relation to birth autoantibody status in offspring of T1D mothers

10

8

6

4

2

0108642

% w

ith m

ultip

le A

bs

Age (years)

POS GADA or IA2A at birthn = 476

NEG GADA and IA2A at birthn = 244

P = 0.007

Koczwara et al, Diabetes 2004

Father T1D

A. Ziegler